Search Results - "GERBER, JOHN G"

Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers by Kiser, Jennifer J, Gerber, John G, Predhomme, Julie A, Wolfe, Pamela, Flynn, Devon M, Hoody, Dorie W

“…OBJECTIVES:This open-label, single-arm, pharmacokinetic (PK) study in HIV-seronegative volunteers evaluated the bioequivalence of rosuvastatin and…”
Get full text

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group by Dubé, Michael P., Stein, James H., Aberg, Judith A., Fichtenbaum, Carl J., Gerber, John G., Tashima, Karen T., Henry, W. Keith, Currier, Judith S., Sprecher, Dennis, Glesby, Marshall J.

Get full text

Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19 by Gerber, John G., Rhodes, Robert J., Gal, Joseph

“…Methadone is a clinically used opioid agonist that is oxidatively metabolized by cytochrome P450 (CYP) isoforms to a stable metabolite, EDDP. Methadone is a…”
Get full text

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 by FICHTENBAUM, Carl J, GERBER, John G, ROSENKRANZ, Susan L, SEGAL, Yoninah, ABERG, Judith A, BLASCHKE, Terrence, ALSTON, Beverly, FANG FANG, KOSEL, Bradley, AWEEKA, Francesca

“…Lipid lowering therapy is used increasingly in persons with HIV infection in the absence of safety data or information on drug interactions with antiretroviral…”
Get full text

Antiretroviral Drug Pharmacokinetics in Hepatitis with Hepatic Dysfunction by Wyles, David L., Gerber, John G.

“…Chronic viral hepatitis is common among persons with HIV-1 infection, because of shared modes of transmission, and coinfection results in accelerated liver…”
Get full text

Effect of Concomitantly Administered Rifampin on the Pharmacokinetics and Safety of Atazanavir Administered Twice Daily by ACOSTA, Edward P, KENDALL, Michelle A, HAAS, David W, GERBER, John G, ALSTON-SMITH, Beverly, KOLETAR, Susan L, ZOLOPA, Andrew R, AGARWALA, Sangeeta, CHILD, Michael, BERTZ, Richard, HOSEY, Lara

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals by Acosta, Edward P, Wu, Hulin, Hammer, Scott M, Yu, Song, Kuritzkes, Daniel R, Walawander, Ann, Eron, Joseph J, Fichtenbaum, Carl J, Pettinelli, Carla, Neath, Denise, Ferguson, Elaine, Saah, Alfred J, Gerber, John G

“…BACKGROUND:Pharmacokinetic enhancement of protease inhibitors (PIs) with low-dose ritonavir (RTV) for salvage therapy is increasingly common. The purpose of…”
Get full text

Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates by Dilmaghanian, Shahrzad, Gerber, John G., Filler, Scott G., Sanchez, Angela, Gal, Joseph

“…Racemic ketoconazole (KTZ) was the first orally active azole antifungal agent used in clinical practice and has become widely used in the treatment of mucosal…”
Get full text

The Pharmacokinetics of Amprenavir, Zidovudine, and Lamivudine in the Genital Tracts of Men Infected with Human Immunodeficiency Virus Type 1 (AIDS Clinical Trials Group Study 850) by Pereira, Arlene S., Smeaton, Laura M., Gerber, John G., Acosta, Edward P., Snyder, Sally, Fiscus, Susan A., Tidwell, Richard R., Gulick, Roy M., Murphy, Robert L., Eron, Joseph J.

“…The AIDS Clinical Trials Group Study 850 (ACTG 850) evaluated the penetration of zidovudine (ZDV), lamivudine (3TC), and amprenavir (APV), given alone and in…”
Get full text

Abacavir Pharmacokinetics in Hepatic Dysfunction by Wyles, David L., Gerber, John G.

Get full text

Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel by Schambelan, Morris, Benson, Constance A, Carr, Andrew, Currier, Judith S, Dubé, Michael P, Gerber, John G, Grinspoon, Steven K, Grunfeld, Carl, Kotler, Donald P, Mulligan, Kathleen, Powderly, William G, Saag, Michael S

“…OBJECTIVE:Alterations in glucose and lipid metabolism, lactic acidemia, bone disorders, and abnormal body fat distribution have been recognized recently as…”
Get full text

Influence of age on arterial baroreflex inhibition of sympathetic nerve activity in healthy adult humans by Davy, K P, Tanaka, H, Andros, E A, Gerber, J G, Seals, D R

“…Resting levels of muscle sympathetic nerve activity (MSNA) increase markedly with age in healthy adult humans. An age-related reduction in arterial baroreflex…”
Get full text

Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186 by Gerber, John G, Kitch, Douglas W, Fichtenbaum, Carl J, Zackin, Robert A, Charles, Stéphannie, Hogg, Evelyn, Acosta, Edward P, Connick, Elizabeth, Wohl, David, Kojic, E Milu, Benson, Constance A, Aberg, Judith A

“…INTRODUCTION:Fish oil has been shown to reduce serum triglyceride (TG) concentrations. In HIV-infected patients on antiretroviral therapy, high TG…”
Get full text

Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study by Gerber, John G, Rosenkranz, Susan L, Fichtenbaum, Carl J, Vega, Jose M, Yang, Amy, Alston, Beverly L, Brobst, Susan W, Segal, Yoninah, Aberg, Judith A

“…Efavirenz (EFV) is associated with hyperlipidemia when used in combination with other antiretroviral drugs. EFV is a mixed inducer/inhibitor of cytochrome P450…”
Get full text

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection by FICHTENBAUM, Carl J, GERBER, John G

“…Treatment of HIV infection with potent combination antiretroviral therapy has resulted in major improvement in overall survival, immune function and the…”
Get full text

Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir by Haas, David W, Koletar, Susan L, Laughlin, Laura, Kendall, Michelle A, Suckow, Carol, Gerber, John G, Zolopa, Andrew R, Bertz, Richard, Child, Michael J, Hosey, Lara, Alston-Smith, Beverly, Acosta, Edward P

“…BACKGROUND:Rifampin is the cornerstone of antituberculosis therapy, but induction of hepatic cytochrome P4503A by rifampin markedly lowers HIV protease…”
Get full text

Protein binding in antiretroviral therapies by Boffito, Marta, Back, David J, Blaschke, Terrence F, Rowland, Malcolm, Bertz, Richard J, Gerber, John G, Miller, Veronica

“…There is marked variability in the extent to which the three classes of antiretroviral (ARV) drugs bind to plasma proteins (<5 to >99%). Protease inhibitors…”
Get more information

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers by Glesby, Marshall J., Aberg, Judith A., Kendall, Michelle A., Fichtenbaum, Carl J., Hafner, Richard, Hall, Stephen, Grosskopf, Nicole, Zolopa, Andrew R., Gerber, John G.

“…Background Hypertension is an important modifiable cardiac risk factor in human immunodeficiency virus (HIV)‐infected patients. Calcium channel blockers are…”
Get full text

Stereoselective determination of the epimer mixtures of itraconazole in human blood plasma using HPLC and fluorescence detection by Pyrgaki, Christina, Bannister, Steve J., Gera, Lajos, Gerber, John G., Gal, Joseph

“…Itraconazole is an antifungal drug widely used in a variety of fungal infections, which have become a significant public‐health problem in recent decades…”
Get full text

The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors: Implications for Once-Daily Dosing by Back, David J, Burger, David M, Flexner, Charles W, Gerber, John G

“…The trend toward once-daily dosing in HIV antiretroviral therapy is based on the association between adherence, treatment outcome, and patient preferences…”
Get full text